Pyoderma gangrenosum
Ko te Pyoderma gangrenosum he mate kiri onge, ā, ka puta ngā pustules māmae me ngā nodules hei whewhe ka tipu haere. Pyoderma gangrenosum ehara i te hopuhopu. Ko ngā maimoatanga ka uru ki ngā corticosteroids, cyclosporin, ētahi momo paturopi monoclonal rānei. Ahakoa ka pā ki ngā tāngata ahakoa te pakeke, ko te nuinga ka pā ki ngā tāngata i waenganui i te 40 me te 50 tau.
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Kei te tangata he ulcerative colitis.
relevance score : -100.0%
ReferencesKo te Pyoderma gangrenosum he mate kiri onge, e puta ai ngā whewhe māmae me ngā tapa whero, papura rānei. Kua whakarōpūtia hei mate mumu, he wāhanga o te rōpū e kīia nei ko te neutrophilic dermatoses. He uaua te mārama i te take o te Pyoderma gangrenosum; he raruraru kei roto i te pūmautanga me te urutau i roto i ngā tangata e pā ana ki te ira. I tata nei, kua aro ngā kairangahau ki te makawe-makawe hei timatanga o te mate.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Ko te Pyoderma gangrenosum he mate kiri onge e puta ai ngā whewhe tino mamae. Ahakoa kāore mātou i te tino mārama ki tōna take, e mōhio ana mātou he nui ake ngā mahi a ētahi o ngā pūtau mate. Kāore i te māmā te rongoā mō tēnei mate. He maha ngā rārangi rongoā e pehi ana i te pūnaha raupatu, hei whakarerekē rānei i tāna mahi. I te taha o ēnei, ka aro anō mātou ki te rongoā i ngā patunga me te whakahaere i te mamae. Ko ngā corticosteroids me te cyclosporine te nuinga o ngā wā ko te whiriwhiri tuatahi mō te maimoatanga, engari i ēnei rā, kua nui ake ngā rangahau mō te whakamahi rongoā kōiora pērā i te aukati TNF-α. He pai ake ēnei kōiora, inā koa i ngā turoro me ētahi atu mate mumura, ā, ka whakamahia i mua atu i te tukanga mate.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
